File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intensive Palliative Care for Patients With Hematological Cancer Dying in Hospice: Analysis of the Level of Medical Care in the Final Week of Life

TitleIntensive Palliative Care for Patients With Hematological Cancer Dying in Hospice: Analysis of the Level of Medical Care in the Final Week of Life
Authors
Keywordsdying
hematology
hospice
intensive
oncology
palliative care
Issue Date2015
Citation
American Journal of Hospice and Palliative Medicine, 2015, v. 32, n. 2, p. 221-225 How to Cite?
AbstractDying of hematological oncology patients often take place in respective hematology ward or intensive care unit rather than hospice. With the increased attention to quality palliative care for hematology patients, concerns regarding their level of medical care at end-of-life need to be addressed. We conducted a retrospective review of consecutive hematological oncology patients who succumbed in a palliative unit between July 2012 and August 2013. The primary outcome measure was their level of medical care received, including administration of antibiotics, total parenteral nutrition, blood sampling, GCSF injection and blood products transfusion, during their last seven days of life. During the last seven days of life, 85.7 % of patients had blood sampling and 23.8% of patients received G-CSF injection. Total parenteral nutrition was administered in 14.3% of patients. One-third of patients received transfusion of packed cells and nearly half of them received transfusion of platelet concentrates. Almost 90% of patients received antibiotics during their last week of life. Collaboration between hematology and palliative care has resulted in successful transition of hematologic cancer patients into hospice unit in their terminal phase of illness. However, their level of medical care, even approaching last seven days of life, remained intensive. Proper allocation of medical resources and future research regarding optimal end-of-life care for hematology patients are warranted.
Persistent Identifierhttp://hdl.handle.net/10722/352131
ISSN
2023 Impact Factor: 1.5
2023 SCImago Journal Rankings: 0.706

 

DC FieldValueLanguage
dc.contributor.authorCheng, Benjamin Hon Wai-
dc.contributor.authorSham, Michael Mau Kwong-
dc.contributor.authorChan, Kwok Ying-
dc.contributor.authorLi, Cho Wing-
dc.contributor.authorAu, Ho Yan-
dc.date.accessioned2024-12-16T03:56:53Z-
dc.date.available2024-12-16T03:56:53Z-
dc.date.issued2015-
dc.identifier.citationAmerican Journal of Hospice and Palliative Medicine, 2015, v. 32, n. 2, p. 221-225-
dc.identifier.issn1049-9091-
dc.identifier.urihttp://hdl.handle.net/10722/352131-
dc.description.abstractDying of hematological oncology patients often take place in respective hematology ward or intensive care unit rather than hospice. With the increased attention to quality palliative care for hematology patients, concerns regarding their level of medical care at end-of-life need to be addressed. We conducted a retrospective review of consecutive hematological oncology patients who succumbed in a palliative unit between July 2012 and August 2013. The primary outcome measure was their level of medical care received, including administration of antibiotics, total parenteral nutrition, blood sampling, GCSF injection and blood products transfusion, during their last seven days of life. During the last seven days of life, 85.7 % of patients had blood sampling and 23.8% of patients received G-CSF injection. Total parenteral nutrition was administered in 14.3% of patients. One-third of patients received transfusion of packed cells and nearly half of them received transfusion of platelet concentrates. Almost 90% of patients received antibiotics during their last week of life. Collaboration between hematology and palliative care has resulted in successful transition of hematologic cancer patients into hospice unit in their terminal phase of illness. However, their level of medical care, even approaching last seven days of life, remained intensive. Proper allocation of medical resources and future research regarding optimal end-of-life care for hematology patients are warranted.-
dc.languageeng-
dc.relation.ispartofAmerican Journal of Hospice and Palliative Medicine-
dc.subjectdying-
dc.subjecthematology-
dc.subjecthospice-
dc.subjectintensive-
dc.subjectoncology-
dc.subjectpalliative care-
dc.titleIntensive Palliative Care for Patients With Hematological Cancer Dying in Hospice: Analysis of the Level of Medical Care in the Final Week of Life-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1177/1049909113512412-
dc.identifier.pmid24259405-
dc.identifier.scopuseid_2-s2.0-84922735479-
dc.identifier.volume32-
dc.identifier.issue2-
dc.identifier.spage221-
dc.identifier.epage225-
dc.identifier.eissn1938-2715-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats